Oncolytic virus adjunct therapy with agents that increase virus infectivity
US10238700B2 · kind B2 · utility
8Cited by
83References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 31, 2014 |
| Grant date | Mar 26, 2019 |
| Priority date | — |
| Expiry date | Sep 8, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/24132
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are adjunct therapies for use in combinations and compositions with an oncolytic virus, such as a vaccinia virus. The adjunct therapies include co-administration and co-formulation of a complement inhibitor and/or a lipid emulsion composition with the oncolytic virus. Also provided herein are therapeutic methods using the adjunct therapies for treatment of disease and conditions employing an oncolytic therapeutic virus, such as for the treatment of hyperproliferative diseases or conditions including tumors or cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.